# JSP191 (briquilimab) in Subjects with LR-MDS

> **NCT05903274** · PHASE1 · TERMINATED · sponsor: **Jasper Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Lower-risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** JSP191

## Key facts

- **NCT ID:** NCT05903274
- **Lead sponsor:** Jasper Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-19
- **Primary completion:** 2024-10-21
- **Final completion:** 2024-10-21
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was terminated due to a lack of improvement in clinical efficacy outcomes.
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05903274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05903274, "JSP191 (briquilimab) in Subjects with LR-MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05903274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*